SEKISUI XenoTech is a contract research organization (CRO) specializing in nonclinical drug metabolism & drug-drug interaction studies. Over 25 years, we have grown to serve 98% of the top pharma companies (as well as medium, small and virtual pharma, biotechs, research institutions & universities, and more) by assisting them with pharmacokinetics-related safety studies for the drug candidates they are developing, usually before clinical trials. Our leadership and expertise is trusted by industry professionals and academics alike to provide not only superior services and products, but also industry-leading research and new techniques. There’s a lot of nuance to understanding pharmacokinetic properties of drug candidates. How they enter/exit specific cells, how long they stay, how they get metabolized by enzymes and what metabolites result—all these properties make up the research area called ADME (Absorption, Distribution, Metabolism and Excretion). ADME represents a key area of preclinical investigation to determine whether a drug is going to be dangerous to someone and to make sure it’s in the correct dose and form to produce the therapeutic effect it’s meant to. In vitro and in vivo studies planned with a consultative approach and tailored study design are key to achieving useful, reliable ADME data. Drug-drug interactions (DDIs) are a preventable cause of adverse drug reactions which kill or hurt 350,000 hospitalized patients per year. DDI potential can be evaluated using in vitro data and is encouraged by regulatory authorities to be appropriately investigated early in a drug’s development. Our clients come to us because we are global experts in predicting potential DDI issues in the lab before they could happen in a clinical trial volunteer. Doing these studies earlier and with a trusted expert not only instills confidence in your data, but saves money and reduces your risk of late-stage failure.